L12.31 ICD-10-CM Code: Epidermolysis bullosa due to drug
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Diseases of the skin and subcutaneous tissue (L00-L99) / Bullous disorders (L10-L14)
L12.31
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceEpidermolysis bullosa due to drug
A blistering skin condition caused by a medication or drug that the patient is taking, where the immune system attacks the skin layers.
Buddy Insight
Drug-induced epidermolysis bullosa represents medication-related autoimmune skin fragility that may improve with drug discontinuation.
CMS-HCC V28
00
RAF 0
CMS-HCC V24
MappedHCC 162
RAF 0.517
ACA/HHS
00
RAF 0
ESRD/PACE
MappedHCC 162
RAF 0.0
RXHCC
00
RAF 0
Code Trumping
Basket needed
Code Book Path
Inclusion Terms
OfficialICD-10-CM does not list inclusion terms for L12.31 in this effective period.
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for L12.31 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for L12.31 in this effective period.
Excludes 1
Official- epidermolysis bullosa (congenital) (Q81.-)
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for L12.31 in this effective period.
Use Additional
Official- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Code Also
OfficialICD-10-CM does not list Code Also instructions for L12.31 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.
Is L12.31 an HCC code?
Yes. L12.31 maps to Severe Skin Burn or Condition under the V24 model but is not retained in V28.
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for L12.31
For L12.31to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed L12.31 during that encounter, not just copy-forwarded from a problem list.
What This Code Means
L12.31 is the ICD-10-CM diagnosis code for epidermolysis bullosa due to drug. A blistering skin condition caused by a medication or drug that the patient is taking, where the immune system attacks the skin layers. L12.31 sits in the ICD-10-CM chapter for diseases of the skin and subcutaneous tissue (l00-l99), within the section covering bullous disorders (l10-l14).
Under the older CMS-HCC V24 model, L12.31 maps to Severe Skin Burn or Condition (HCC 162) with a community, non-dual, aged base RAF weight of 0.517. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Always identify and document the specific drug causing the reaction; use an additional code from T36-T50 for the drug if applicable. Because L12.31 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for L12.31 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
Clinical Significance
Drug-induced epidermolysis bullosa represents medication-related autoimmune skin fragility that may improve with drug discontinuation. This diagnosis is important for medication safety and may have a better prognosis than idiopathic forms.
Documentation Requirements
- ✓Temporal relationship between drug exposure and symptoms
- ✓Identification of causative medication
- ✓Clinical presentation consistent with epidermolysis bullosa
- ✓Histopathologic and immunological confirmation
- ✓Documentation of drug discontinuation
- ✓Response to drug withdrawal
- ✓Alternative medication planning
- ✓Wound care management